Skip to main content

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Real-Time Last Update
Volume
Day Low2.800
Day High2.840
Open:2.840
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest News

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
Globe Newswire - Mon Feb 14, 6:30AM CST
Globe Newswire
Mon Feb 14, 6:30AM CST
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...
Shares for Interest Debt Settlement
Globe Newswire - Tue Feb 8, 6:44PM CST
Globe Newswire
Tue Feb 8, 6:44PM CST
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
Globe Newswire - Tue Jan 4, 6:25AM CST
Globe Newswire
Tue Jan 4, 6:25AM CST
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

Latest Articles